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Abstract
Introduction: We compared the effectiveness of tenofovir/emtricitabine (TDF/FTC) combined with either lopinavir/r (LPV/r)
or another recommended third drug in the 2010 French guidelines in antiretroviral-naı¨ve patients starting combination
antiretroviral therapy in 20042008 in the French Hospital Database on HIV.
Methods: The outcomes were stop or switch of the third component, viral load (VL) B500 copies/ml, an increase of at least 100
CD4 cells/mm3, AIDS-defining event and non-AIDS-defining hospitalization or death. Propensity scores were estimated by logistic
regression based on the clinical centre and other confounders. In each clinical centre, each patient initiating LPV/r was matched
with a patient initiating another third drug (efavirenz or atazanavir/r) and having a close propensity score. Cox’s proportional
hazards models were then used, with treatment as covariate. Time was right-censored at four years.
Results: 1269 patients started LPV/r plus TDF/FTC, and 890 could be matched to 890 patients receiving another third drug.
Baseline characteristics were well balanced between these two groups. LPV/r was associated with a higher risk of third drug stop
(hazard ratio (HR): 1.69; 95% confidence interval (CI), 1.422.00) and with less rapid viral suppression (HR: 0.83; 95% CI, 0.72
0.95). There was no difference in the time required for a CD4 cell increment of at least 100/mm3, or to the occurrence of an
AIDS-defining event. Non-AIDS-defining hospitalizations or deaths were more frequent with LPV/r (HR: 1.79; 95% CI, 1.332.39).
Conclusions: For first-line therapy, in this observational setting, TDF/FTC plus LPV/r were less durable than TDF/FTC plus another
recommended third drug, led to a less rapid viral suppression and were associated with a higher risk of non-AIDS morbidity.
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Introduction
The primary aims of antiretroviral therapy (ART) for HIV
infection are to reduce morbidity and to prolong life by
reducing viral load (VL) and increasing the CD4 T-cell count
with minimal toxicity/adverse event (AE). Combination anti-
retroviral therapy (cART) comprising two nucleoside reverse
transcriptase inhibitors (NRTI) and a third drug, either a
ritonavir-boosted protease inhibitor (PI) or a non-nucleoside
reverse transcriptase inhibitor (NNRTI), has shown good
virologic and immunologic efficacy inmany randomized clinical
trials [19].
The efficacy of ritonavir-boosted PI-containing regimens
relies on the additional dose of ritonavir used as a pharma-
cokinetic booster. Lopinavir/r (LPV/r) has been the boosted PI
of choice formany years, and was the only such co-formulation
available in 2011. Other boosted PI-based regimens with a
more favourable toxicity profile became available as early as
2004.
Between 2004 and 2008, several randomized trials com-
pared various antiretroviral (ARV) drugs in treatment-naı¨ve
patients [39]. In 2008, based on the results of these trials,
American and European guidelines recommended efavirenz
(EFV), LPV/r, atazanavir/r (ATV/r) or fosamprenavir/r (FPV/r)-
based regimens as preferred options for ART-naı¨ve patients
[10,11]. In 2012, EFV and ATV/r were still recommended in
American and European guidelines, but FPV/r was listed as an
alternative. LPV/r was still recommended for ART-naı¨ve
patients in 2010 European guidelines but was listed as an
alternative in US guidelines. These recommendations were
based on virologic efficacy and, to a lesser extent, on the CD4
cell increment and tolerability.
Since ARV drugs are generally not assessed on clinical
criteria, because of limited-duration randomized controlled
trials and low event frequency, it is important to know
whether the various recommended ARV drugs have the same
impact on the basis of clinical criteria defined as AIDS-related
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morbidity or severe non-AIDS morbidity such as malignant,
cardiovascular and infectious diseases. In addition, because
patients enrolled in clinical trials are selected, and for
example individuals with severe comorbidities are often
excluded, clinical trial findings can be less generalizable
than observational study findings, so it is important to assess
the effectiveness of different treatments in routine care
settings, complementarily with clinical trials [12].
The purpose of this study was to assess whether LPV/r was
still a valid option for ART-naı¨ve patients. Using a compara-
tive effectiveness approach, LPV/r was compared to other
recommended third drugs (EFV and ATV/r) in the 2010 French
guidelines, always in combination with tenofovir/emtricita-
bine (TDF/FTC), using five criteria for effectiveness: the
durability of the third component, virologic and immunologic
responses, AIDS morbidity and severe non-AIDS morbidity.
Methods
Patients and data sources
The FHDH-ANRS CO4 (French Hospital Database on HIV,
Agence Nationale de Recherches sur le Sida, cohort 4) is an
open hospital cohort study created in 1992. It includes 70
hospitals belonging to 26 Regional HIV/AIDS Coordination
Centres (COREVIHs) located in mainland France and French
overseas territories. Patients are eligible if they have
documented HIV-1 or HIV-2 infection and give their written
informed consent to participate. Data are collected prospec-
tively by trained research assistants on standardized forms
which include the transmission group, biological markers
such as the CD4 cell count and plasma HIV RNA level, clinical
manifestations, the nature and starting date of prescribed
treatments, and death. The reasons for ARV drugs stopping
have been collected since 2005.
Study population
This study was restricted to ARV-naı¨ve adults and adolescents
living with HIV and with a VL 500 copies/ml, who started a
first-line three-drug cART regimen consisting of TDF/FTC in
every case, plus LPV/r, ATV/r or EFV. The study period for cART
initiation was 20042008. We selected 2004 as this was
the year atazanavir became available, and 2008 in order to
provide four-year results. Women with reported pregnancy
and patients infected less than six months previously were not
eligible, as they qualified for specific therapeutic strategies.
Statistical analysis
The baseline for all analyses was the date of treatment
initiation. The following baseline characteristics were de-
scribed according to the prescribed regimen: clinical centre,
age, sex transmission, sub-Saharan origin, hepatitis C virus
co-infection, time after diagnosis of HIV-1 infection (B1 year
or ]1 year), AIDS status, year of treatment initiation, base-
line CD4 cell count (log2) and VL (log10) and cotrimoxazole
prophylaxis.
Rather than comparisons of LPV/r with each other
recommended third drug, we chose to compare the LPV/r
regimen to the other two regimens combined, after checking
that ATV/r and EFV had similar effectiveness in our study.
Combining ATV/r and EFV into one group also allows one
to diminish the selection bias, the impact of unmeasured
confounders in an observational setting, and to increase the
statistical power in the comparison. In addition, as the
backbone may play a role in the outcomes of interest, we
only studied patients initiating with TDF/FTC.
Biological and clinical responses were compared by using
the propensity score method, which is used in observational
studies to control for systematic differences between non-
randomized treatment groups, thereby reducing the indica-
tion bias and confounding factors [1315]. The propensity
score for each subject, defined as the conditional probability
of receiving LPV/r given his or her individual covariates, was
estimated from a logistic regression model that included
baseline characteristics and the clinical centre. To take into
account a possible clinical centre effect, each patient
initiating LPV/r was matched with a patient who started on
another third drug (EFV or ATV/r) in the same clinical centre
and who had a close propensity score (within 90.04).
Absolute standardized differences were used to compare
the balance in baseline characteristics between two treat-
ment groups [16].
We evaluated four-year Kaplan-Meier estimates for all of the
following outcomes: third component stop or switch; virologic
success, defined as ever achieving a VL B500 copies/ml while
still receiving the drug; a gain of at least 100 CD4 cells/mm3;
AIDS morbidity (AIDS-defining event or death from an AIDS-
defining event); and severe non-AIDS morbidity (non-AIDS
hospitalization or death from a non-AIDS cause). The choice of
threshold (500 copies/ml) was due to assay technique changes
over time in the study period. Cox’s proportional hazards
models were used, including the type of treatment as the only
variable in the model, in the group of patients initiating LPV/r
and their matched counterparts initiating another third drug,
in order to compare outcomes between the two matched
groups. The other third drug (EFV or ATV/r) served as the
reference. Time was right-censored at four years. As a change
in the third drug could be considered as a competing event
(such patients are likely to be those experiencing a slower
reduction in VL or a slower increase in the CD4 cell count), a
competing-risk approach was adopted for virologic and
immunologic responses. In this approach, when the third
drug was changed, follow-up was right-censored at the date of
the patient’s last visit during the four-year follow-up period.
This approach ensures that no endpoint can be recorded
during the period between the treatment change and the end
of the four-year follow-up period, thus avoiding a situation in
which the majority of patients change their third drug and
achieve a VL reduction (or a gain in CD4 cells) while on this
alternative treatment. For both clinical endpoints, we used
an intention-to-continue-treatment approach, ignoring treat-
ment changes. We also described the reasons for stopping or
switching the third drug as follows: ineffective treatment,
intolerance and/or toxicity/adverse event, treatment simplifi-
cation and other reasons. We used SAS software (v9.2; SAS
Institute Inc., Cary, NC, USA) for all statistical analyses.
Results
Patients enrolled and baseline characteristics
The flow chart of the study is shown in Figure 1. A total of
3424 patients were included, of whom 1269 started LPV/r
Vale´rie Potard et al. Journal of the International AIDS Society 2014, 17:19070
http://www.jiasociety.org/index.php/jias/article/view/19070 | http://dx.doi.org/10.7448/IAS.17.1.19070
2
plus TDF/FTC and 2155 started EFV (n1441) or ATV/r
(n714) plus TDF/FTC. Several characteristics of the two
initial treatment groups were different (Table 1, Unmatched).
The propensity scores of the two treatment groups showed
substantial overlap (Supplementary Figure 1), allowing 890
patients (70%) to be matched. Unmatched patients (n379)
had more advanced HIV infection, with lower CD4 cell counts
(median 81 vs. 223), higher VL (median 5.2 vs. 4.9) and more
frequent prior AIDS-defining event (40% vs. 17%). Absolute
standardized differences comparing baseline characteristics
between the two groups in the unmatched and matched
samples are reported in Supplementary Figure 2. After
propensity score matching, the standardized differences of
all the characteristics were less than 10%, indicating a
successful balance.
The third drug was EFV in 614 cases (69%) and ATV/r in
276 cases (31%). Median follow-up was 42.0 months (inter-
quartile range: 26.455.2).
Outcomes
No difference was found between EFV and ATV/r on any of
the outcomes. Figure 3 shows Kaplan-Meier plots of the
different outcomes and corresponding hazard ratios (HRs) for
LPV/r compared to another third drug up to four years after
treatment initiation.
Durability of treatment
Of the 890 matched patients initiating LPV/r, 517 patients
changed their treatment, and of the 890 patients initiating
another third drug, 310 patients changed their treatment.
FHDH ANRS CO4 
HIV 1 infected patients >15 years
who initiated a first line cART with VL>500
excluding pregnant women and patients
within 6 months of infection
between 2004 and 2008
N=9905
Initiating with one of the three cART studied:
TDF/FTC and LPV/r, or ATV/r or EFV
N=3589
(3483 patients initiating with one of the 3 3rd drug
under study using another backbone, 795 patients
initiated with a TDF/FTC backbone but another
3rd drug and 2038 initiated with other regimen)
Follow-up after cART initiation
N=3488
One measurement of CD4 obtained within 3
months prior to cART initiation
N=3442
With known date of HIV diagnosis
With known date of AIDS onset
N=3424
95.4%
97.2%
98.7%
99.5%
FHDH ANRS CO4
HIV 1 infected patients >15 years
followed between 2004 and 2008
N=19372 
58.4%
36.2%
Figure 1. Patient flow.
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The flow chart in Figure 2 shows the number of documented
treatment stops according to information that has been
collected (known VL within three months before the stop and
the reason for stop available in the database).
Among the 267 patients who changed their third drug
after VL B500 copies/ml and for whom the reason for
the change was available, these reasons differed between the
treatment groups (pB0.0001). Among toxicity/adverse event
the proportion of patients with lipid disorders who switched
after initiating LPV/r was 8% versus 0% for patients initiating
another third drug (p0.007). The proportion of switch for
simplification was greater for patients initiating LPV/r than
for patients initiating another third drug. Among the 44
patients who changed their third drug with VL ]500 copies/
ml, the reasons for the change did not differ between the
treatment groups (p0.36).
The estimated proportion of patients who had changed at
month 48 was 70% with LPV/r versus 42% with the other
third drugs. The LPV/r-containing regimen was significantly
less durable than the other regimens (HR1.69; 95%
confidence interval (CI), 1.422.00) (Figure 3a). The esti-
mated proportion of patients who changed their treatment
after achieving virologic success was 63% with LPV/r versus
29% with the other third drugs (HR2.10; 95% CI, 1.67
2.65).
Virologic outcome
VL fell below 500 copies/ml in 759 patients on LPV/r and in
765 patients on the other third drugs. LPV/r was associated
with less rapid viral suppression (pB0.0001) (Figure 3b).
At month three, the rate of virologic success was 48% with
LPV/r versus 56% with the other third drugs (pB0.0001); at
month six, this rate was 76% with LPV/r versus 79% with the
other third drugs (p0.06); whereas the difference was no
longer significant at later times. Overall, the proportion of
virologic success (ever achieving a VL B500 copies/ml while
still receiving the drug) was lower for LPV/r than for another
third drug (HR0.83; 95% CI, 0.720.95).
Immunologic outcome
The CD4 cell count rose by at least 100/mm3 in 658 patients
initiating LPV/r and in 663 patients initiating another third
drug. There was no difference between LPV/r and the other
third drugs with respect to the time required for the CD4 cell
count to rise by at least 100/mm3 (83% for the two groups at
48 months) (Figure 3c).
Clinical outcomes
During the 48 months of follow-up, 161 patients experi-
enced at least one AIDS-defining event (85 in the LPV/r group
and 76 in the other group). Overall, 121 patients experienced
Table 1. Baseline characteristics of patients
Unmatched patients Matched patients
LPV/r (n1269)
EFV, ATV/r
(n2155) p LPV/r (n890)
EFV, ATV/r
(n890)
Age (years) (median [IQR]) 40.0 [33.546.8] 39.5 [32.946.7] 0.41 39.6 [33.546.5] 39.8 [32.647.0]
Sex transmission 0.0004
MSM 418 (33%) 860 (40%) 304 (34%) 324 (36%)
IDU 75 (6%) 94 (4%) 52 (6%) 50 (6%)
Heterosexual men 329 (26%) 564 (26%) 233 (26%) 221 (25%)
Heterosexual women 340 (27%) 490 (23%) 229 (26%) 223 (25%)
Other men 71 (6%) 94 (4%) 46 (5%) 48 (5%)
Other women 36 (3%) 53 (3%) 26 (3%) 24 (3%)
Sub-Saharan origin 317 (25%) 426 (20%) 0.0004 228 (26%) 217 (24%)
HCV positive 119 (9%) 186 (9%) 0.46 90 (10%) 77 (9%)
Time since HIV diagnosis B1 year 710 (56%) 859 (40%) B0.0001 428 (48%) 425 (48%)
CD4 cell count (/mm3) (median [IQR]) 191 [71280] 260 [180326] B0.0001 223 [122300] 237 [146303]
Plasma HIV-1 RNA (log10 copies/ml) (median
[IQR])
5.00 [4.445.50] 4.78 [4.285.20] B0.0001 4.89 [4.335.40] 4.88 [4.355.28]
Prior AIDS 305 (24%) 285 (13%) B0.0001 155 (17%) 157 (18%)
Prophylaxis (yes) 565 (45%) 605 (28%) B0.0001 336 (38%) 338 (38%)
Year of starting cART B0.0001
2004 16 (1%) 81 (4%) 13 (2%) 10 (1%)
2005 77 (6%) 247 (12%) 61 (7%) 65 (7%)
2006 329 (26%) 515 (24%) 225 (25%) 223 (25%)
2007 417 (33%) 497 (23%) 264 (30%) 261 (29%)
2008 430 (34%) 815 (38%) 327 (37%) 331 (37%)
LPV/rlopinavir/r; EFVefavirenz; ATV/ratazanavir/r; IQRinterquartile range; MSMmen who have sex with men; IDUinjectable drug
users; HCVhepatitis C virus; cARTcombination antiretroviral therapy; Bold values indicate that P is significant (B0.05).
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one AIDS-defining event, 31 patients experienced two, seven
patients experienced three and two patients experienced
four. Among the 212 AIDS-defining event, the five most
frequent were tuberculosis (n43 individuals and 52 events;
18 patients with extrapulmonary tuberculosis, 16 with
pulmonary tuberculosis and 9 with both extrapulmonary
and pulmonary tuberculosis during the follow-up), Kaposi’s
sarcoma (n33), Pneumocystis jiroveci pneumonia (n23),
cerebral toxoplasmosis (n16) and oesophageal candidiasis
(n15). There was no difference in the occurrence of AIDS-
defining event or deaths from an AIDS-defining event
between LPV/r and the other third drugs (10% vs. 9% at 48
months) (Figure 3d).
During the 48 months of follow-up, 237 patients experi-
enced at least one non-AIDS-hospitalization or death (153 with
LPV/r and 84 with the other third drugs). One-third of
hospitalizations were for non-AIDS-defining infection (n
91). The other four most common reasons for non-AIDS
hospitalization were chronic viral hepatitis (n13), non-
AIDS-efining malignancies (n12), haematologic disorders
(n12) and psychiatric disorders (n9). Four patients on
LPV/r and two of the patients on another third drug were
hospitalized for cardiovascular disease. LPV/r was associated
with a higher risk of non-AIDS morbidity with an HR of 1.79
(95%CI, 1.332.39) compared to the other third drugs (21% vs.
12% at 48 months) (Figure 3e).
Discussion
In this large observational study, after taking into account the
propensity for receiving LPV/r, LPV/r was associated with
shorter treatment durability, less rapid viral suppression and
a higher risk of severe non-AIDS morbidity when compared
to other recommended third drugs. No difference was found
between LPV/r and the other third drugs with respect to
immunologic efficacy or AIDS morbidity.
Two strengths of our study were the large sample size
and the use of propensity scores to control for confound-
ing factors in this observational setting. One limitation is
that 30% of patients receiving LPV/r could not be matched.
However, their clinical outcomes tended to be worse,
and this cannot therefore explain the worse clinical outcomes
we observed among the LPV/r-treated patients in our
analysis.
Although the propensity score method cannot control for
unmeasured confounders, the most important ones in terms
of prognosis were taken into account in our analyses, except
for adherence as no adherence data are available in the
FHDH. Our decision to compare LPV/r to all other recom-
mended third drugs combined instead of separately limited
the possibility of a strong unmeasured confounder. Our
choice to combine EFV and ATV/r was clinically justified
because these drugs are recommended ‘‘third drugs’’ in the
n = 827 stop or switch
LPV/r: 517   Other: 310
known VL within 3 months
before treatment change
n=740
Unknown VL but reason
of treatment change available
n=40
No available data  
n=47
LPV/r: 466    Other: 274 LPV/r: 20 Other: 20 LPV/r: 31  Other: 16
Toxicity:        7 (35%)     9 (45%)
Simplif.:        8 (40%)     2 (10%)
Inef. Treat.:   1 (5%)       4 (20%)
Other reas.:  4 (20%)     5 (25%)
VL<500 copies/ml
n=559
VL≥500 copies/ml
n=181 
LPV/r: 378    Other: 181 LPV/r: 88     Other: 93
Reason of treatment
change available
n=267
Reason of treatment
change available
n=44
LPV/r: 180      Other: 87 LPV/r: 19       Other: 25
Toxicity:       78 (43%)       34 (39%) Toxicity:       10 (53%)        15 (60%)
Simplif.:       75 (42%)        9 (10%) Simplif.:          1(5%)            2 (8%)
Inef. Treat.:   9 (5%)         14 (16%) Inef. Treat.:   4 (21%)          7 (28%)
Other reas.: 18 (10%)       30 (35%) Other reas.:  4 (21%)          1 (4%)
Figure 2. Stop or switch treatment flow.
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guidelines. In the ACTG A5202 randomized trial, ATV/r was as
efficacious and well tolerated as EFV [6].
We restricted our study to a single NRTI backbone (TDF
plus FTC) in order to be able to compare the impact of the
third drug. Indeed, it has been reported that the choice of
NRTI backbone is a significant predictor of virologic success
and treatment failure [1719]. Finally, in our analysis of
biological responses, any change in the third component was
considered to represent treatment failure. This approach may
better reflect the effectiveness of the third component, as
changes in treatment may be due to either inefficiency or
intolerance. Unfortunately, reason for treatment change was
missing in 57.6% of the 827 stops or switches of the third
component.
The rate of stop or switch was larger in patients receiving
LPV/r than in patients receiving another third drug, in
keeping with the results of the CORIS study [20]. Here, the
most frequent reason for treatment changes was toxicity/
adverse event, as in other observational studies [2022].
Toxicity remains a major cause of treatment discontinuation,
and for LPV/r the simplification is also an important reason to
stop this drug. Many patients who changed their treatment
after achieving virologic success did so for reasons of
simplification (42% in the LPV group). This reflects a strategy
in which a PI/r-based regimen is prescribed first to ensure
less resistance in case of failure and is then replaced by a
simpler regimen that is also more tolerable in the long term
[23]. The great increase in the number of switching events
in patients on LPV/r over time could indicate the availability
of novel and simpler therapies gaining popularity among
practitioners. The rate of treatment discontinuation tended
to be higher in this observational study than in clinical trials,
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Figure 3. Kaplan-Meier plots showing the time (a) to stop or switch the third component, (b) to achieve a virologic response of viral load
B500 copies/ml, (c) to gain at least 100 CD4 cells/mm3, (d) to the occurrence of an adverse event (AE) or death from an AE, and (e) to the
occurrence of a non-AE hospitalization or death.
Vale´rie Potard et al. Journal of the International AIDS Society 2014, 17:19070
http://www.jiasociety.org/index.php/jias/article/view/19070 | http://dx.doi.org/10.7448/IAS.17.1.19070
6
possibly because patients with severe comorbidities and
biological abnormalities are often excluded from clinical trials
[2,4,24].
The initial difference in virologic efficacy before six
months, between LPV/r and the other third drugs, disap-
peared after 12 months. A comparative effectiveness study
also showed that differences between regimens in terms of
virologic efficacy were not as pronounced over time [25].
Likewise, in the NORTHIV trial, EFV was superior to LPV/r at
48 weeks (69% vs. 86%), but at 144 weeks there was no
significant difference between the two groups [26]. However,
in the CASTLE randomized trial, the proportions of patients
who achieved a VL B50 copies/ml were similar in the LPV/r
and ATV/r groups at week 48 (76% vs. 78%), but fewer
patients receiving LPV/r had HIV RNA B50 copies/ml at
week 96 compared to patients receiving ATV/r (68% vs. 74%)
[3]. In the ACTG 5142 randomized trial, a greater early effect
of EFV compared with LPV/r on suppression of HIV RNA levels
(B50 copies/ml) has been reported at week 96 (77% vs.
89%) [5]. The lack of difference at two years in our study may
have been due to the use of a less strict virologic endpoint
(HIV RNA B500 copies/ml) than in recent clinical trials.
Despite the more rapid virologic efficacy of the other third
drugs compared to LPV/r during the first six months of our
study, the gain in CD4 cells was similar. In clinical trials, no
significant difference in the CD4 cell gain from baseline was
found at week 48 between the ATV/r and LPV/r and the EFV
and LPV/r groups [3,5,9,26].
Regarding clinical outcomes, although there was no sig-
nificant difference in AIDS morbidity between the LPV/r and
comparator regimens, we found that LPV/r was associated
with a higher risk of non-AIDS morbidity. Clinical trials lacked
sufficient power to detect differences in clinical outcomes
[2,4,9,24,26]. Causes of hospitalization were similarly distrib-
uted in the two groups, although their frequency was higher
with LPV/r. Although LPV/r has been linked to lipid disorders,
we noted no increase in the risk of hospitalization for
cardiovascular diseases among patients receiving LPV/r
[2,4,9,24]. Among the causes of hospitalization, we noted a
lot of non-AIDS-defining infection. Higher risk of non-AIDS
morbidity among patients receiving LPV/r could be perhaps
explained by the slower rate of reduction in VL that we
observed after initiating treatment, which could affect non-
AIDS-defining infection occurrence in these patients.
Conclusions
This study shows that first-line cART with LPV/r is less
durable, provides less rapid viral suppression and is asso-
ciated with more frequent severe non-AIDS clinical events
than other recommended third drugs. These findings support
recommendations that LPV/r should be considered as an
alternative rather than as a preferred drug for cART-naı¨ve
patients, as done in the 2013 French and European guidelines
where LPV/r was listed as an alternative [11,27].
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